Cover Image
市場調查報告書

放射線障礙:開發平台分析

Radiation Injury - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 335688
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
放射線障礙:開發平台分析 Radiation Injury - Pipeline Review, H1 2015
出版日期: 2015年06月17日 內容資訊: 英文 50 Pages
簡介

放射線障礙是由於曝露於電離放射線造成的組織損傷。依曝露部位為全身或是限定部位不同而有所不同。全身受到高輻射劑量照射的情況為急性幅射傷害,身體局部的情況則為局部性放射線障礙。

本報告提供放射線障礙的治療藥開發情形調查分析,提供您開發中的產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

放射線障礙概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Atox Bio Inc.
  • Cleveland BioLabs, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Humanetics Corporation
  • PharmaIN Corporation
  • RestorGenex Corporation

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AB-103
  • BIO-300
  • C-2E5
  • CBLB-613
  • HSJ-0017
  • Recombinant Protein to Activate FGF-4 for Radiation Injury
  • Recombinant Protein to Activate FGF-7 for Radiation Injury
  • RES-529
  • Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury
  • Small Molecules to Activate Vitamin D Receptor for Radiation Injury

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

附錄

圖表

目錄
Product Code: GMDHC6796IDB

Summary

Global Markets Direct's, 'Radiation Injury - Pipeline Review, H1 2015', provides an overview of the Radiation Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiation Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Radiation Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Radiation Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Radiation Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Radiation Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Radiation Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Radiation Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Radiation Injury Overview
  • Therapeutics Development
    • Pipeline Products for Radiation Injury - Overview
    • Pipeline Products for Radiation Injury - Comparative Analysis
  • Radiation Injury - Therapeutics under Development by Companies
  • Radiation Injury - Therapeutics under Investigation by Universities/Institutes
  • Radiation Injury - Pipeline Products Glance
    • Early Stage Products
  • Radiation Injury - Products under Development by Companies
  • Radiation Injury - Products under Investigation by Universities/Institutes
  • Radiation Injury - Companies Involved in Therapeutics Development
    • Atox Bio Inc.
    • Cleveland BioLabs, Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Humanetics Corporation
    • PharmaIN Corporation
    • RestorGenex Corporation
  • Radiation Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-2E5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBLB-613 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSJ-0017 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RES-529 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Vitamin D Receptor for Radiation Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Radiation Injury - Recent Pipeline Updates
  • Radiation Injury - Dormant Projects
  • Radiation Injury - Dormant Projects
  • Radiation Injury - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Radiation Injury, H1 2015
  • Number of Products under Development for Radiation Injury - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Investigation by Universities/Institutes, H1 2015
  • Radiation Injury - Pipeline by Atox Bio Inc., H1 2015
  • Radiation Injury - Pipeline by Cleveland BioLabs, Inc., H1 2015
  • Radiation Injury - Pipeline by Cumberland Pharmaceuticals, Inc., H1 2015
  • Radiation Injury - Pipeline by Humanetics Corporation, H1 2015
  • Radiation Injury - Pipeline by PharmaIN Corporation, H1 2015
  • Radiation Injury - Pipeline by RestorGenex Corporation, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Radiation Injury Therapeutics - Recent Pipeline Updates, H1 2015
  • Radiation Injury - Dormant Projects, H1 2015
  • Radiation Injury - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Radiation Injury, H1 2015
  • Number of Products under Development for Radiation Injury - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top